{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:49:07Z","timestamp":1769852947831,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,15]],"date-time":"2017-01-15T00:00:00Z","timestamp":1484438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.afos.2017.01.002","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T02:01:01Z","timestamp":1487210461000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Denosumab for the treatment of osteoporosis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-0778","authenticated-orcid":false,"given":"Michael R.","family":"McClung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2017.01.002_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1138\/20090378","article-title":"The epidemiology of osteoporosis in Asia","volume":"6","author":"Lau","year":"2009","journal-title":"IBMS BoneKey"},{"key":"10.1016\/j.afos.2017.01.002_bib2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.afos.2017.01.002_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.afos.2017.01.002_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.afos.2017.01.002_bib5","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nm1197-1285","article-title":"Osteopetrosis in mice lacking NF-kappaB1 and NF-kappa B2","volume":"3","author":"Iotsova","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.afos.2017.01.002_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.afos.2017.01.002_bib7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00198-007-0363-7","article-title":"The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys","volume":"18","author":"Ominsky","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1749-6632.2012.06674.x","article-title":"The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction","volume":"1263","author":"Goessl","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.afos.2017.01.002_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A\u00a0single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2017.01.002_bib12","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2017.01.002_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/GME.0b013e318267f909","article-title":"Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.afos.2017.01.002_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib20","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/2230-8210.146871","article-title":"A\u00a0randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis","volume":"19","author":"Pitale","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","article-title":"Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension","volume":"57","author":"Koh","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.afos.2017.01.002_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bone.2011.08.007","article-title":"A\u00a0randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women","volume":"49","author":"Kumagai","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib27","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib30","first-page":"1953","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib31","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.afos.2017.01.002_bib32","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","article-title":"Denosumab in treatment-na\u00efve and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers","volume":"64","author":"Anastasilakis","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.afos.2017.01.002_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2017.01.002_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2017.01.002_bib37","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jocd.2012.02.014","article-title":"Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis","volume":"16","author":"McClung","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.afos.2017.01.002_bib39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2013.07.011","article-title":"Improvements in hip trabecular, subcortical, and cortical density\u00a0and mass in postmenopausal women with osteoporosis treated with denosumab","volume":"56","author":"Genant","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbmr.2325","article-title":"Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis","volume":"30","author":"Poole","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jbmr.2024","article-title":"Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab","volume":"29","author":"Keaveny","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2015.06.025","article-title":"Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element\u00a0methodology","volume":"81","author":"Zysset","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib43","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jbmr.2855","article-title":"Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis","volume":"31","author":"Zebaze","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study","volume":"30","author":"Tsai","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib46","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib47","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib48","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib49","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","article-title":"Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years","volume":"26","author":"Ferrari","year":"2015","journal-title":"Osteoporos Int"},{"issue":"Suppl. 2","key":"10.1016\/j.afos.2017.01.002_bib50","first-page":"S471","article-title":"Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial","volume":"75","author":"Bone","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib51","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib52","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.afos.2017.01.002_bib53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin","volume":"299","author":"Heiss","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.afos.2017.01.002_bib54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report","author":"Lamy","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib56","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/14737167.2016.1171145","article-title":"Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost","volume":"16","author":"Chodick","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.afos.2017.01.002_bib58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","article-title":"Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study","volume":"26","author":"Silverman","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib59","article-title":"Persistence and compliance with osteoporosis therapies among women in a commercially insured population in the United States","volume":"21","author":"Cheng","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.afos.2017.01.002_bib60","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","article-title":"Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis","volume":"26","author":"Karlsson","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib61","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","article-title":"Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study","volume":"26","author":"Hadji","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib62","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-016-3886-y","article-title":"Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years","author":"Modi","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib66","article-title":"Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study","author":"Choi","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib67","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.39075","article-title":"Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.afos.2017.01.002_bib68","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5694\/mja13.10038","article-title":"Severe symptomatic hypocalcaemia following a single dose of denosumab","volume":"199","author":"McLachlan","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.afos.2017.01.002_bib69","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","article-title":"Identification of the risk factors associated with hypocalcemia induced by denosumab","volume":"36","author":"Okada","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.afos.2017.01.002_bib70","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/imj.13097","article-title":"Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease","volume":"46","author":"Killen","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.afos.2017.01.002_bib71","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.afos.2017.01.002_bib72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13223-015-0097-6","article-title":"Monoclonal antibody desensitization in a patient with a generalized urticarial reaction\u00a0following denosumab administration","volume":"11","author":"Guti\u00e9rrez-Fern\u00e1ndez","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.afos.2017.01.002_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2013.06.004","article-title":"Denosumab and atypical femur fractures","volume":"76","author":"Cating-Cabral","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.afos.2017.01.002_bib74","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","article-title":"Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review","volume":"27","author":"Selga","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2017.01.002_bib75","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2106\/JBJS.K.00774","article-title":"Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial","volume":"94","author":"Adami","year":"2012","journal-title":"J\u00a0Bone Jt Surg Am"},{"key":"10.1016\/j.afos.2017.01.002_bib76","unstructured":"Prolia\u00ae prescribing information [Internet] Accessed January 10, 2017. Available from: http:\/\/pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/prolia\/prolia_pi.ashx."},{"key":"10.1016\/j.afos.2017.01.002_bib77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00223-015-0075-5","article-title":"Denosumab inhibition of RANKL and insulin resistance in postmenopausal women with osteoporosis","volume":"98","author":"Lasco","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2017.01.002_bib78","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jbmr.2043","article-title":"RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk","volume":"29","author":"Samelson","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib79","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/pds.3477","article-title":"Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia\u00ae (denosumab) for the treatment of postmenopausal osteoporosis","volume":"22","author":"Xue","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.afos.2017.01.002_bib80","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib81","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib82","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/jbmr.2236","article-title":"Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension","volume":"29","author":"Brown","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib83","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A\u00a0comprehensive\u00a0review of denosumab for bone metastasis in patients with solid\u00a0tumors","volume":"32","author":"G\u00fcl","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.afos.2017.01.002_bib85","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A\u00a0randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib86","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A\u00a024-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib87","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9992","key":"10.1016\/j.afos.2017.01.002_bib88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"361","key":"10.1016\/j.afos.2017.01.002_bib89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2017.01.002_bib90","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib91","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","article-title":"Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates","volume":"69","author":"Dore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.afos.2017.01.002_bib92","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.afos.2017.01.002_bib93","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00223-016-0150-6","article-title":"Treatment of Paget's disease of bone with denosumab: case report and literature review","volume":"99","author":"Reid","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2017.01.002_bib94","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/ajt.13692","article-title":"Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial","volume":"16","author":"Graf","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.afos.2017.01.002_bib95","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.137516","article-title":"Effects of the anti-receptor activator of nuclear factor kappa B ligand denosumab on beta thalassemia major-induced osteoporosis","volume":"18","author":"Yassin","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.afos.2017.01.002_bib96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2016.08.025","article-title":"Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab","volume":"92","author":"Adami","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.afos.2017.01.002_bib97","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect \u2013 a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J\u00a0Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.afos.2017.01.002_bib98","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2017.01.002_bib99","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.afos.2017.01.002_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23133","article-title":"Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study","author":"Yue","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525517300043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525517300043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T13:26:31Z","timestamp":1601645191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525517300043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2405525517300043"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2017.01.002","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab for the treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2017.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}